Bolni Marius Nagalo

Federal Grant PI

Associate Professor

UAMS

Also affiliated: University of Maryland, Baltimore (2025–2026); Université Joseph Ki-Zerbo (2011–2023); Mayo Clinic (2017–2024); Endicott College (2014); University of Arkansas Medical Center (2022–2025); Centre Hospitalier Universitaire Yalgado Ouédraogo (2013); Mayo Clinic in Arizona (2017–2024); Mayo Clinic Hospital (2020–2022); Université des Sciences et Techniques de Masuku (2013–2019); National Cancer Institute (2025–2026); University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (2025–2026); Mayo Clinic Comprehensive Cancer Center (Arizona) (2020–2021)

19 h-index 108 pubs 1,259 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Bolni Marius Nagalo's research focuses on understanding and developing therapeutic strategies for various diseases, with a significant emphasis on cancer. He has received federal funding from the NIH/National Cancer Institute for work on targeting the cGAS-STING pathway to treat hepatocellular carcinoma and from the NIH/NIH Office of the Director for novel strategies to enhance drug delivery and tumor immunogenicity in pancreatic cancer. His work involves investigating the tumor microenvironment as a therapeutic target and exploring immunovirotherapy approaches.

Nagalo's research also extends to infectious diseases, as indicated by publications on the seroprevalence of HIV, hepatitis B and C viruses, and syphilis among blood donors in Burkina Faso, as well as toxoplasmosis and rubella in pregnant women. He has also explored the biological interactions of viral vectors, such as the interaction of ChAdOx1 with CAR and PF4, with implications for thrombosis. Additionally, his research interests include investigating the properties and activities of essential oils from plants used in traditional medicine, such as Cymbopogon nardus, and their potential anti-inflammatory and antiproliferative effects, as demonstrated in studies on psoriasis-like inflammation.

With a h-index of 18 and over 100 publications, Nagalo has established a productive research career. He leads a research group at the University of Arkansas for Medical Sciences and collaborates with several colleagues within the institution, including Steven R. Post, Mulu Z. Tesfay, Khandoker Usran Ferdous, and Martin J. Cannon.

Metrics

h-index: 19
Publications: 108
Citations: 1,259

Positions

Associate Professor 2025–present

University of Maryland School of Medicine Pharmacology & Physiology ORCID
Associate Professor publications 2021–2026

University of Arkansas for Medical Sciences ORCID
Assistant Professor 2021–2025

University of Arkansas for Medical Sciences Pathology ORCID

Selected Publications

Loss of FAM60A disrupts Sin3/HDAC control of the Hippo signaling and promotes oncogenic YAP1 activation (2026)

Cell Death and Disease DOI OpenAlex
Plasma proteomic profiling reveals distinct protein signatures associated with hepatocellular carcinoma in chronic hepatitis B infection (2026)

Clinical Proteomics DOI OpenAlex
Prognostic factors and survival outcomes in colorectal cancer: insights from a Ghanaian cohort (2025)

BMC Gastroenterology 1 citation DOI OpenAlex
The impact of the timing of adjuvant treatment initiation in patients with upfront resection of pancreatic cancer (2025)

Surgical Oncology 1 citation DOI OpenAlex
Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)

ACS Pharmacology & Translational Science 1 citation DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
HDAC3 mediates retinal endothelial cell metabolic reprogramming and angiogenesis (2025)

Acta Pharmacologica Sinica 1 citation DOI OpenAlex
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
Abstract 950: Engineered oncolytic vesiculovirus downsizes pancreatic tumor and boosts immune response (2025)

Cancer Research DOI OpenAlex
Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer (2025)

Cancer Research DOI OpenAlex
Abstract 2792: PiRNA as a novel therapeutic in hepatocellular carcinoma: insights from population screening (2025)

Cancer Research 1 citation DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

Cancer Research DOI OpenAlex
Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059) (2025)

Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells (2025)

Journal of Clinical and Translational Science DOI OpenAlex
Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma (2025)

Molecular Therapy Oncology 3 citations DOI OpenAlex